GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » E10

Karyopharm Therapeutics (FRA:25K) E10 : €-2.81 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Karyopharm Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.294. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-2.81 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-23), Karyopharm Therapeutics's current stock price is €0.8862. Karyopharm Therapeutics's E10 for the quarter that ended in Mar. 2024 was €-2.81. Karyopharm Therapeutics's Shiller PE Ratio of today is .


Karyopharm Therapeutics E10 Historical Data

The historical data trend for Karyopharm Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics E10 Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -3.70 -2.66 -2.92

Karyopharm Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.65 -2.89 -3.02 -2.92 -2.81

Competitive Comparison of Karyopharm Therapeutics's E10

For the Biotechnology subindustry, Karyopharm Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Shiller PE Ratio falls into.



Karyopharm Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Karyopharm Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.294/131.7762*131.7762
=-0.294

Current CPI (Mar. 2024) = 131.7762.

Karyopharm Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.405 100.560 -0.531
201409 -0.473 100.428 -0.621
201412 -0.641 99.070 -0.853
201503 -0.684 99.621 -0.905
201506 -0.820 100.684 -1.073
201509 -0.757 100.392 -0.994
201512 -0.744 99.792 -0.982
201603 -0.674 100.470 -0.884
201606 -0.748 101.688 -0.969
201609 -0.615 101.861 -0.796
201612 -0.616 101.863 -0.797
201703 -0.664 102.862 -0.851
201706 -0.570 103.349 -0.727
201709 -0.545 104.136 -0.690
201712 -0.676 104.011 -0.856
201803 -0.633 105.290 -0.792
201806 -0.514 106.317 -0.637
201809 -0.677 106.507 -0.838
201812 -0.844 105.998 -1.049
201903 -0.965 107.251 -1.186
201906 -0.628 108.070 -0.766
201909 -0.608 108.329 -0.740
201912 -0.684 108.420 -0.831
202003 -0.706 108.902 -0.854
202006 -0.559 108.767 -0.677
202009 -0.620 109.815 -0.744
202012 -0.485 109.897 -0.582
202103 -0.647 111.754 -0.763
202106 -0.589 114.631 -0.677
202109 -0.587 115.734 -0.668
202112 0.407 117.630 0.456
202203 -0.481 121.301 -0.523
202206 -0.587 125.017 -0.619
202209 -0.455 125.227 -0.479
202212 -0.406 125.222 -0.427
202303 -0.280 127.348 -0.290
202306 -0.268 128.729 -0.274
202309 -0.281 129.860 -0.285
202312 -0.330 129.419 -0.336
202403 -0.294 131.776 -0.294

Add all the adjusted EPS together and divide 10 will get our e10.


Karyopharm Therapeutics  (FRA:25K) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Karyopharm Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics (FRA:25K) Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines